1105 Effects and mechanisms of tranilast in inhibiting keloid fibrosis

L. Haiyang,T. Ying,L. Juiming,S. Xiangguang,W. Wu
DOI: https://doi.org/10.1016/j.jid.2023.03.1117
IF: 7.59
2023-01-01
Journal of Investigative Dermatology
Abstract:Keloids are benign skin tumors caused by excessive proliferation of collagen fibers following skin injury. Due to Tranilast’s ability in inhibiting transforming growth factor-β(TGF-β) and proliferation of fibroblasts, it is used in the treatment of keloid. However, its specific mechanisms concerning anti-fibrosis has not been fully elucidated. Therefore, this study intends to investigate the effects of Tranilast on keloid fibroblasts(KF) and explore their mechanisms by transcriptomics. We found that tranilast inhibited the proliferation of KF in a dose-dependent manner. The scratch width of the tranilast treatment group was significantly lower than that of the control group at 24 hours and 48 hours after scratching(P<0.05). Tranilast significantly reduced the expression of collagen and α-SMA mRNAs and inflammatory factor IL1β in KF (P<0.05). Transcriptomic studies have shown that tranilast can up-regulate cAMP signaling pathway and inflammatory mediator regulation pathway of TRP channel, down-regulate FoxO pathway, cellular senescence pathway and cell cycle-related pathway related to TGF-β, thereby inhibiting KF proliferation, extracellular matrix(ECM) accumulation and cellular inflammation. These results suggest that tranilast exerts anti-fibrotic effects by inhibiting the proliferation, migration, inflammatory response, ECM accumulation and fibroblast activation of KF.
What problem does this paper attempt to address?